جستجوی استاد راهنمای دانشگاهی

Benjamin Simonsمشاهده پروفایل

استاد

• Stem Cell Biology
• Developmental Biology
• Cancer Biology
• +۳ مورد دیگر

Benjamin Simons is the Royal Society EP Abraham Professor and Herchel Smith Professor of Physics at the University of Cambridge. He serves as Director of the Gurdon Institute, Senior Group Leader at the Gurdon Institute, Principal Investigator at the Cambridge Stem Cell Institute, and member of the Theory of Condensed Matter physics group. He is also a Fellow of St. John's College, Cambridge. His research integrates quantitative approaches from physics and mathematics with experimental biology to investigate stem cell fate regulation in tissue development, maintenance, and cancer pathogenesis. Research focuses on: Stochastic cell fate decisions in epithelial tissues Self-organization principles in tissue morphogenesis Single-cell lineage tracing and gene expression analysis Mathematical modeling of stem cell dynamics Cancer initiation through stem cell reprogramming Publication analysis reveals consistent themes: spatial dynamics of stem cell niches, mechanical regulation of cell fate, computational modeling of tissue organization, and evolutionary principles in cancer development. Recent work emphasizes in vivo lineage tracing, single-cell omics, and interdisciplinary approaches bridging physics and biology. Scientific Awards: Fellow of the Royal Society (FRS) Fellow of the Academy of Medical Sciences (FMedSci) Leads an interdisciplinary research group combining wet-lab experiments (lineage tracing, single-cell genomics) with theoretical modeling. Research supported by EPSRC, MRC, Wellcome Trust, Cancer Research UK, and Royal Society grants. Current projects include gliomagenesis mechanisms, spermatogenic wave regulation, and injury response pathways co-opted in cancer.

Ellen Rothenbergمشاهده پروفایل

استاد

• Cellular and Developmental Biology
• Molecular Biology
• Immunology
• +۳ مورد دیگر

Ellen Rothenberg is the Edward B. Lewis Professor of Biology at the California Institute of Technology (Caltech). She earned her A.B. in Biochemical Sciences from Harvard University (1972) and a Ph.D. in Molecular Biology from MIT (1977). Her academic career at Caltech spans roles from Assistant Professor (1982–88) to her current position. She holds the Ruddock Professorship (2007–21), Distinguished Professor (2021–), and Lewis Professor (2021–). Her research focuses on transcriptional networks governing T-cell development and signaling, particularly how hematopoietic stem cells commit to T-lymphocyte lineages. Using in vitro systems, molecular genetics, and genomic approaches, her lab explores transcription factor interactions, chromatin dynamics, and signaling pathways that drive T-cell identity. Key interests include understanding stem-cell multipotentiality loss, irreversible commitment mechanisms, and links to autoimmune predisposition. Rothenberg is an Andrew D. White Professor-at-Large at Cornell University (2021–2027), collaborating with immunology and molecular biology departments. She has organized international conferences, served on NIH review panels, and advises biotech firms like Century Therapeutics. Her honors include membership in the National Academy of Sciences, AAAS and American Academy of Arts and Sciences fellowships, and the Feynman Teaching Prize (2016). Education: A.B., Harvard University, Biochemical Sciences, 1972 Ph.D., Massachusetts Institute of Technology, Molecular Biology, 1977 Awards: AAAS Fellow, American Academy of Arts and Sciences Fellow Member, National Academy of Sciences American Association of Immunologists Distinguished Fellow Richard P. Feynman Prize for Excellence in Teaching (2016) External Roles: Cornell’s ADW-PAL (2021–2027), collaborating with faculty hosts Brian Rudd and Andrew Grimson Scientific Advisor, Century Therapeutics, A2 Biotherapeutics, Kite Pharma Her work bridges basic research and clinical applications, including immunogenomics symposia and public lectures on T-cell programming. Ongoing projects explore evolutionary origins of lymphocyte development through comparative analysis of basal vertebrates.

Dean Tantinمشاهده پروفایل

استاد

• Gene regulation in T cells
• T cell memory and autoimmunity
• Stem cell biology
• +۴ مورد دیگر

Dean Tantin is a Professor of Microbiology and Immunology at the University of Utah School of Medicine, where his research delves into gene regulation in T cells, stem cells, and cancer. His lab investigates how transcription factors like Oct1, Oct4, and OCA-B control stem-like properties in cells, impacting immunological memory, autoimmunity, and cancer progression. Education: B.S. – University of California, San Diego Ph.D. – University of California, Los Angeles Research Interests: Dr. Tantin’s work centers on understanding how transcription factors regulate cell fate decisions, particularly in T cells and stem cells. His lab explores the roles of Oct1 and Oct4 in pluripotency and differentiation, the function of OCA-B in T cell memory and autoimmunity, and the therapeutic potential of targeting these factors in diseases like multiple sclerosis and type 1 diabetes. A major focus is on how these transcription factors control gene expression programs that endow cells with longevity, self-renewal, and rapid response capabilities. Article Trends: Recent publications highlight a strong emphasis on transcriptional regulation in immune cells, particularly CD4+ T cells, and stem cells. Studies explore how OCA-B and Oct factors influence T cell memory formation, autoimmune responses, and cancer development. The work bridges molecular mechanisms with translational applications, including potential drug targets for autoimmune diseases and cancer. Laboratory and Team: Dr. Tantin leads an active research group at the University of Utah, supported by training grants and core facilities. His lab employs molecular biology, genomics, and in vivo models to dissect transcriptional networks. While specific student names are not listed, his mentorship is evident through his involvement in bioscience PhD programs and collaborative projects.

• Biophysics
• Gene Regulatory Networks
• Immune System Dynamics
• +۶ مورد دیگر

Aleksandra Walczak is a Professor of Biophysics at the École normale supérieure , leading research at the Laboratoire de Physique Théorique (LPENS). Her work bridges statistical physics and biology, focusing on understanding complex living systems through gene regulatory networks, immune system dynamics, and population genetics. Research Interests : Non-equilibrium biological systems, T-cell/B-cell receptor repertoires, stochastic molecular systems, and evolutionary dynamics. Funding & Collaborations : Supported by the Fondation Bettencourt Schueller, she co-organizes interdisciplinary workshops like the Paris Workshop on Immunology and contributes to GDRI Evolution, Regulation and Signaling network. Recent Publications explore gene regulatory principles, immune repertoire modeling, viral-immune coevolution, and collective behavior. She has secured competitive grants and mentors students in theoretical biophysics. Awards : Habilitation à diriger des recherches (2012), Princeton Center for Theoretical Physics Postdoctoral Fellowship (2007-2010). Students & Positions : Actively supervises PhD/Master projects; offers internships in biophysics and quantum engineering.

Sara Ekمشاهده پروفایل

استاد

• Lymphoma
• B Cell Lymphomas
• Cancer and Oncology
• +۴ مورد دیگر

Sara Ek is a Professor and Deputy Head of Department at the Department of Immunotechnology within the Faculty of Engineering (LTH) at Lund University. She serves as Principal Investigator at the Lund University Cancer Centre (LUCC), Director of Create Health, and is a Researcher in the eSSENCE: The e-Science Collaboration. Her academic profile demonstrates a strong commitment to advancing cancer research, particularly in lymphoid malignancies. Dr. Ek's research program, "Cancer Target Group– molecular and functional analysis in lymphoid proliferative disorders," focuses on finding biological solutions to clinically important questions involving improved diagnosis, stratification, and treatment of lymphoma patients. Recognizing that cancer heterogeneity presents a major challenge to successful treatment, her team develops tools to capture this heterogeneity and identify variations in tumor-related signaling pathways and interactions with the immune microenvironment. This work involves close collaboration with clinicians to perform advanced molecular investigations using sequencing, spatial omics technologies, serum protein profiling, and functional screening of patient materials from clinical trials. Her publication record reveals a consistent trajectory of impactful research in lymphoma, particularly mantle cell lymphoma, with groundbreaking work on the SOX11 transcription factor as a diagnostic biomarker. More recently, her research has expanded into spatial analysis of tumor immune microenvironments across different cancer types, including ovarian cancer. This evolution demonstrates her ability to leverage emerging technologies to address complex questions in cancer biology. Active Projects: A cellular and molecular dissection of the lymphoma tumor immune microenvironment to understand and address treatment resistances (2025-2028) MULTIPLY: MULITlayer Predictive models for relapsed MCL after ibrutinib as first line therapy (2024-2027) Primary ibrutinib resistance in mantle cell lymphoma – translational immuno-oncology investigations (2024-2026) Dr. Ek manages the SpatialOmics@LU infrastructure facility and has organized multiple scientific events including the LUCC Immunology minisymposium on digital spatial profiling in February 2024, demonstrating her leadership in both research and academic community building.

Wu Tuoqiمشاهده پروفایل

استادیار

• Immunology
• Cancer Immunotherapy
• T-cell Biology
• +۳ مورد دیگر

Tuoqi Wu is an Assistant Professor in the Department of Immunology at UT Southwestern Medical Center, Dallas, TX. He is also a member of the Harold C. Simmons Comprehensive Cancer Center. Previously, he held an Assistant Professor position in the Department of Immunology and Microbiology at the University of Colorado School of Medicine (2019-2021), alongside memberships in the Human Immunology and Immunotherapy Initiative and University of Colorado Cancer Center. His expertise bridges immunology and molecular biology with a focus on T-cell functionality in chronic infections and cancer. Dr. Wu earned a dual Bachelor of Science degree in Biotechnology and Computer Science from Peking University in 2007. He completed his Ph.D. in Biological and Biomedical Sciences at Emory University (2013) under Dr. Rafi Ahmed in the Department of Microbiology and Immunology. Postdoctoral training at NIH (2013-2019) further refined his research skills in immunological mechanisms. His research investigates molecular pathways governing CD8+ T-cell differentiation, exhaustion, and stemness using cutting-edge techniques like single-cell transcriptomics and epigenomics. Key areas include STING signaling, KEAP1/NRF2 redox regulation, and BACH2/FOXP1 transcriptional control. Applications span antiviral immunity, cancer immunotherapy (CAR T cells), and immune checkpoint blockade efficacy in melanoma. Recent publications highlight T-cell immune landscapes in cancer patients, aging effects on cytotoxic T-cells, and computational tools like Benisse for B-cell analysis. His work emphasizes translating molecular insights into clinical immunotherapies to improve treatment outcomes. No scientific awards were mentioned in the provided text. His advising includes PhD students Ziang Zhu (focused on T-cell immunology) and Safuwra Wizzard (clinically oriented research). Postdoctoral researchers Ying Luo and Taidou Hu contribute expertise in T-cell exhaustion and epigenetic regulation. Grant funding details are not included here, though institutional memberships suggest active research support. Dr. Wu leads the Wu Lab at UTSW, a multidisciplinary team exploring T-cell biology, CAR T-cell engineering, and immune dysfunction in chronic diseases. The lab’s work integrates experimental immunology with bioinformatics to address unresolved challenges in antitumor and antiviral immunity.

Sandra Pohlمشاهده پروفایل

استاد

• Lysosomal storage disorders
• Mucolipidosis type II and III
• Osteogenesis imperfecta
• +۵ مورد دیگر

Prof. Dr. Sandra Pohl is a full Professor at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the Department of Osteology and Biomechanics. Her research focuses on lysosomal storage disorders, particularly mucolipidosis types II and III, and their systemic effects on bone, cartilage, kidney and the central nervous system. She employs mouse models, human genetic studies and translational approaches to dissect disease mechanisms and develop therapeutic strategies. Education & Training No specific educational details provided in the source material; only the academic title "Prof. Dr. (PhD)" is listed. Research Interests Prof. Pohl’s work centers on: Molecular pathology of mucolipidosis type II (I-cell disease) and type III (pseudo-Hurler polydystrophy). GlcNAc-1-phosphotransferase biology and its role in lysosomal enzyme targeting. Skeletal manifestations of lysosomal storage disorders, including osteopenia, cartilage degeneration and dysostosis multiplex. Neurocognitive outcomes and CNS imaging in mucolipidosis patients. Enzyme replacement therapy design and evaluation in pre-clinical mouse models. Proteostasis, autophagy and ubiquitin-proteasome system interactions in disease pathogenesis. Publication Trends Between 2020 and 2024, Prof. Pohl has published extensively on the intersection of lysosomal dysfunction and skeletal/renal/neurological pathology. Her recent articles emphasize: Genotype–phenotype correlations in GNPTAB/GNPTG variants. Translational mouse models recapitulating human mucolipidosis. Multi-omics profiling (proteomics, imaging, metabolomics) to uncover disease biomarkers. Interdisciplinary studies linking basic cell biology to clinical manifestations. Research Support & Collaborations Prof. Pohl currently leads or co-leads the following initiatives: SFB 877, Teilprojekt B03: “Proteolysis-ver” (exact title abbreviated in source) – a collaborative research center funded by the German Research Foundation (DFG). Cross-institutional consortia involving nephrologists, neurologists, geneticists and imaging specialists across Germany and internationally. Laboratory & Core Facilities Her team utilizes state-of-the-art core facilities provided by UKE, including: Transgenic mouse core Advanced imaging and microscopy Mass-spectrometry-based proteomics High-throughput sequencing and bioinformatics platforms

Akhilesh Kumarمشاهده پروفایل

استادیار

• Hematopoietic Stem Cell Biology
• T Cell Development
• Cancer Immunotherapy
• +۳ مورد دیگر

Akhilesh Kumar, PhD, serves as an Assistant Professor in the Department of Medicine at the University of Minnesota Medical School, specializing within the Division of Hematology, Oncology & Transplantation. His academic appointment bridges regenerative medicine and oncology, focusing on the development of novel cellular therapies through stem cell engineering and immunological research. Dr. Kumar's research program centers on hematopoietic stem cell differentiation, with particular emphasis on T cell and natural killer cell development from pluripotent stem sources. His work investigates molecular regulators like BCL11B in lymphoid specification and explores therapeutic targets such as DLL3 in neuroendocrine tumors. Current projects include engineering multi-antigen targeting cellular therapies for thoracic cancers and multiple myeloma, generating vasculogenic cell populations for regenerative applications, and enhancing natural killer cell function through metabolic modulators like nicotinamide. This research integrates stem cell biology, immunology, and translational oncology to address unmet needs in cancer treatment. Analysis of Dr. Kumar's recent publications (2023-2025) reveals a strong translational focus with significant contributions to hematopoietic development and cancer immunotherapy. His team has pioneered methods for arterial hemogenic endothelium production, elucidated transcription factor networks in blood cell specification, and advanced clinical applications including NK cell therapy for lymphoma. The work demonstrates interdisciplinary reach, spanning from basic mechanisms of lymphoid development to computational approaches in drug delivery and building aerodynamics, reflecting collaborative efforts across engineering, computational biology, and clinical oncology domains.

Terhi Hannele Kärpänenمشاهده پروفایل

مدرس

• Molecular Biology
• Functional Genetics
• Developmental Biology
• +۵ مورد دیگر

Terhi Hannele Kärpänen serves as a Lecturer at Nord University, where she teaches Molecular Cell Biology (BI210F) and actively supervises graduate research. Her academic foundation includes a PhD in Biomedical Sciences from the University of Helsinki (2006), establishing her expertise in molecular and developmental biology. Education: PhD in Biomedical Sciences, University of Helsinki, Finland (2006) Research Focus: Dr. Kärpänen's work centers on molecular regulation of early embryonic development through small regulatory RNAs, with significant contributions to lymphangiogenesis and cancer biology. Her competence spans lymphatic tumor metastasis, lymphedema mechanisms, and cancer immunotherapy development. She employs zebrafish models and molecular genetics to investigate vascular development pathways, particularly VEGF-C/VEGFR-3 signaling and lymphatic vessel formation. Publication Landscape: Her 15 most recent publications (2023-2008) reveal consistent focus on lymphatic system biology, with increasing emphasis on immunotherapy applications. Key trends include molecular dissection of VEGF-C activation mechanisms, genetic regulation of embryonic lymphangiogenesis, and translational T-cell receptor therapies for leukemia. Her work bridges basic developmental biology with oncological applications, frequently utilizing zebrafish models for in vivo validation. Academic Mentorship: Dr. Kärpänen has supervised 1 BSc and 4 MSc theses, demonstrating commitment to undergraduate and master's education. She currently co-supervises 3 PhD students, indicating active engagement in doctoral training and research leadership within her specialized fields.

Ana Cumanoمشاهده پروفایل

استاد

• Immunology
• Hematopoiesis
• Lymphocyte Development
• +۳ مورد دیگر

Ana Cumano is a Professor at the Pasteur Institute and Research Director of Exceptional Class at INSERM, leading the Lymphopoiesis Unit with over four decades of groundbreaking research in immunology and hematopoiesis. She received her Doctoral degree in Medicine from the New University of Lisbon in 1980 and completed postdoctoral training at the Genetics Institute in Cologne and the Ontario Cancer Institute in Toronto before joining the Pasteur Institute in 1992. Her research focuses on lymphocyte development, particularly T cell development in the thymus, with significant contributions to understanding the waves of embryonic, fetal, and postnatal multi-lymphoid progenitors. Dr. Cumano's laboratory has pioneered the use of spectral cytometry for deep immunophenotyping and revealed fundamental insights into how bone marrow monocytes sustain NK cell development during liver inflammation through IL-15 trans-presentation and osteopontin secretion. Her recent publications demonstrate a consistent trajectory of innovative research, with 2025 work on spatiotemporal dynamics of fetal liver hematopoietic niches, 2024 studies on NK cell development during non-alcoholic steatohepatitis and high-dimensional spectral cytometry, and 2023 publications mapping human lymphopoiesis revealing differential regulation of B and T/NK/ILC lineages. Her research has established that lymphoid specification follows independent direct or stepwise hierarchical routes converging toward CD117lo multi-lymphoid progenitors. EMBO Member (2000-2014) National ARC Commission for Immunology, Microbiology, and Hematopoiesis (2009-2011, Vice-president 2012-2014) Scientific Council of the Pasteur Institute (2009-2013) COMESP Pasteur Institute member (2014-present) HERM Advisory Board, Stockholm (2014-present) As an educator, Dr. Cumano co-directs the Advanced Immunology course at the Pasteur Institute and has mentored numerous students and postdoctoral fellows. Her laboratory continues to investigate the role of lncRNA H19 in thymopoiesis and the developmental cartography of human lymphopoiesis, with implications for understanding immune disorders, blood cancers, and immunodeficiency conditions.

Jennifer E. Creminsمشاهده پروفایل

دانشیار

• Chromatin architecture
• Spatial neurobiology
• 3D genome organization
• +۷ مورد دیگر

Jennifer E. Cremins is an Associate Professor and Deans' Distinguished Scholar in Engineering and Medicine at the University of Pennsylvania, with primary appointments in the Department of Bioengineering and secondary appointment in Genetics. She leads the Cremins Laboratory, which works at the spatial biology-technology interface to investigate the structure-function relationship of connections across the scales of chromatin, synapses, and circuits in the developing and diseased mammalian brain. Dr. Cremins' research focuses on understanding how the genome's three-dimensional architecture influences neural development, function, and disease. Her lab has made foundational contributions to elucidating chromatin's higher-order folding patterns at kilobase-resolution during neural lineage commitment, maturation, activity stimulation, and in neurological disorders. The lab's work bridges chromatin folding, synaptic plasticity, and neurophysiology to elucidate how the genome's structure-function relationship influences synaptic defects in neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. Analysis of Dr. Cremins' recent publications reveals a strong focus on the relationship between chromatin architecture and neurological disorders, particularly Alzheimer's disease, fragile X syndrome, and autism spectrum disorders. Her work increasingly integrates computational approaches with experimental techniques to study genome organization at single-cell resolution, with significant emphasis on the role of short tandem repeat expansions in neurodegenerative conditions. Dr. Cremins' laboratory has received significant recognition through numerous scientific awards and fellowships: Deans' Distinguished Scholar in Engineering and Medicine Funding from New York Stem Cell Foundation, Alfred P. Sloan Foundation Support from National Science Foundation, National Institutes of Health (NIMH, NINDS) Grants from Friedreich's Ataxia Research Alliance, Chan Zuckerberg Initiative Funding from Cure Huntington's Disease Initiative, NIH 4D Nucleome Common Fund As an educator and mentor, Dr. Cremins has developed the SEEDS (Summer Exploration in Epigenetics and Data Science) program, a four-year interdisciplinary training program for undergraduates. All 15 graduates of her SEEDs/SEEDs-BRIDGE programs remain in scientific careers, including PhD programs at MIT and UPenn, MD-PhD programs at Mayo, UCSF, and NYU, and MD programs at various institutions. She also develops structured active learning courses focused on statistics, probability, and coding for spatial epigenetics data analysis. The Cremins Laboratory maintains a vibrant research environment with multiple postdoctoral fellows, graduate students, and undergraduate researchers working at the intersection of chromatin biology, neuroscience, and computational genomics. The lab is particularly known for its work on the 4D nucleome and its relationship to neurological disorders, using cutting-edge techniques like Oligopaints imaging and developing computational tools like FISHnet for analyzing chromatin architecture.

Tyler B Moranمشاهده پروفایل

استادیار

• Cardiology
• Cardio-Oncology
• Pericardial Disease
• +۵ مورد دیگر

Tyler B Moran, M.D., Ph.D., is an Assistant Professor in the Department of Medicine – Cardiology at Baylor College of Medicine. He is also a member of the Dan L. Duncan Comprehensive Cancer Center. Dr. Moran is a non-invasive cardiologist at the Baylor Heart Clinic with a focus on general cardiology, disease prevention, and cardio-oncology. He serves as the Director of Research for the cardiology fellowship program and is actively involved in training medical students, residents, and fellows. His research spans two major domains: molecular mechanisms in hematopoiesis and transcriptional regulation from his early work, and clinical cardiology with a focus on cancer-related cardiovascular complications. His early research involved studying transcription factors such as GATA-1, RUNX1, and FOG-1 in blood cell development, using models like zebrafish and mouse systems. More recently, his work has transitioned into clinical and translational cardiology, particularly in managing acute coronary syndromes in cancer patients, pericardial disease, and myocardial protection strategies during ischemia-reperfusion injury. His publications reflect a trajectory from basic science to clinical applications in cardiovascular medicine. The trend in his publications shows a shift from fundamental molecular biology (2004–2012) to focused clinical cardiology and cardio-oncology (2020–2025), indicating evolving expertise bridging laboratory science and patient care. His work in both domains emphasizes mechanistic understanding and therapeutic implications. Professional Training and Education: MD-PhD, University of Illinois at Urbana-Champaign – Molecular and Integrative Physiology Residency: Internal Medicine, The Ohio State University Fellowship: Cardiovascular Disease, Baylor College of Medicine Scientific Contributions: Extensive research on transcriptional regulation in hematopoiesis Leadership in cardio-oncology research and education Prominent publications in journals such as Molecular Cell , Genes & Development , Blood , and Current Cardiology Reports Dr. Moran advises trainees through his role as Director of Research in the cardiology fellowship and contributes to institutional research development. He does not currently list named students or grants, but his leadership role implies active mentorship. He is affiliated with the Division of Cardiology and the Dan L. Duncan Comprehensive Cancer Center, where he integrates cardiovascular and oncology research. His future work is likely to expand in cardio-oncology, metabolic cardioprotection, and clinical outcomes in high-risk cardiovascular populations.

• Hematopoietic Stem Cell Biology
• Myeloid Cell Differentiation
• Transcription Factor Regulation
• +۳ مورد دیگر

Roy Drissen is a Postdoctoral Researcher at the Weatherall Institute of Molecular Medicine (University of Oxford) working within the Hematopoietic Stem Cell Genetics department under the Nerlov Group. He holds a PhD from Erasmus MC in Rotterdam and has held postdoctoral positions at the WIMM (2005–2009) and the Centre for Regenerative Medicine in Edinburgh (2009–2012), before returning to the WIMM. PhD: Erasmus MC, Rotterdam (1999–2005) Postdoc: WIMM (2005–2009) Postdoc: Centre for Regenerative Medicine, Edinburgh (2009–2012) Current: WIMM (University of Oxford) Drissen investigates hematopoietic stem cell (HSC) lineage commitment and myeloid cell differentiation using single-cell technologies. His work has revealed dual pathways in myeloid development, particularly focusing on eosinophils, basophils, and mast cells, with implications for myeloid malignancies like systemic mastocytosis. He combines mouse and human models to study normal and malignant hematopoiesis, emphasizing transcription factor regulation and epigenetic programming. His recent publications highlight epigenetic mechanisms in HSC fate restriction (2023), enhancer-driven oncogene synergy in CEBPA/CSF3R mutant AML (2019), and identification of distinct myeloid pathways (2016). His research spans from basic erythroid gene regulation to malignant transformation models, reflecting a trajectory from transcriptional control to cancer biology.

Ageliki Tsagaratouمشاهده پروفایل

استادیار

• Epigenetics
• T cell development
• DNA methylation and demethylation
• +۴ مورد دیگر

Dr. Ageliki Tsagaratou is an Assistant Professor in the Department of Genetics at the University of North Carolina at Chapel Hill School of Medicine, where she leads the Tsagaratou Lab focused on epigenetic mechanisms in immune cell development. Her research program investigates how TET family proteins regulate DNA demethylation and transcriptional networks during T cell differentiation in the thymus and periphery. Her primary research interests include: Epigenetic regulation of T cell lineage specification DNA demethylation mechanisms mediated by TET proteins (TET1, TET2, TET3) Role of 5-hydroxymethylcytosine in immune cell development Mechanisms linking epigenetic dysregulation to autoimmunity and hematological malignancies Transcriptional control of invariant natural killer T cell development Dr. Tsagaratou's laboratory employs genetically modified mouse models, primary cell culture, multiparameter flow cytometry, molecular biology assays, and next-generation sequencing technologies to elucidate epigenetic regulatory mechanisms. Recent publications demonstrate her team's focus on TET protein functions in T cell receptor repertoire formation, T follicular helper cell biology, and malignant transformation pathways. As a mentor, she emphasizes individualized development plans, daily communication, and collaborative problem-solving. Her lab participates in interdisciplinary seminars at UNC's Comprehensive Lineberger Cancer Center and Carolina Chromatin Consortium. The laboratory is located in the Burnett-Womack Building on UNC's Chapel Hill campus.

Bradley Bernsteinمشاهده پروفایل

استاد

• Epigenetics
• Cancer Biology
• Chromatin Regulation
• +۳ مورد دیگر

Bradley Bernstein, M.D., Ph.D., is a Professor of Pathology and Cell Biology at Harvard Medical School and Chair of Cancer Biology at Dana-Farber Cancer Institute. He holds the Richard and Nancy Lubin Family Chair and directs the Broad Institute’s Gene Regulation Observatory and Epigenomics Program. His research focuses on epigenetic mechanisms in development and cancer, including chromatin regulation, bivalent domains, and cancer epigenetics. He has pioneered technologies like ENCODE and advanced understanding of noncoding DNA’s role in gene regulation. His work spans cancer mechanisms, stem cell circuits, and therapeutic resistance. Notable contributions include identifying bivalent chromatin states and linking epigenetic changes to oncogene activation in gliomas. Education: B.S. from Yale University (1992), M.D. and Ph.D. from University of Washington (1999), postdoctoral training at Harvard University. Affiliations include Dana-Farber Cancer Institute, Broad Institute, and Ludwig Institute. Research Interests: Epigenetic gene regulation, chromatin structure, cancer epigenetics, developmental hierarchies, single-cell technologies, and translational applications in oncology. Key areas include bivalent domains, tumor self-renewal, and epigenetic therapies. Awards: Richard and Nancy Lubin Family Chair, Ludwig Institute Investigator. Advising & Grants: Mentor to numerous graduate students and postdocs. Leads large-scale consortia (e.g., ENCODE, BLUEPRINT). Active in technology development for epigenomic mapping. Labs/Teams: Bernstein Lab at Dana-Farber and Broad Institute, Epigenomics Program, and Gene Regulation Observatory. Collaborates widely across academia and industry.